Azithromycin can become deficient

For the treatment of coronavirus infection doctors around the world use a variety of drugs outside of approved indications. In one of the experimental regimens COVID-19 was included the antibiotic azithromycin, although evidence of its effectiveness, writes FierceBiotech. High demand for the drug can lead to its deficit, said the producers.

The largest manufacturers of azithromycin are Teva and Pfizer, they warned about possible delays in the supply despite increasing production.

Azithromycin FDA already included in the list of scarce drugs.

Leave a Reply

Your email address will not be published. Required fields are marked *

Releated

For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]